Bristol Myers Squibb Expands Multiple Myeloma Equity Program with Large-Scale U.S. Survey
Event summary
- Bristol Myers Squibb (BMY) is expanding its Standing in the Gaap program, which has addressed multiple myeloma care gaps for a decade.
- The company is launching a large-scale U.S. survey involving over 1,000 patients, caregivers, and healthcare providers.
- The survey aims to identify persistent barriers in multiple myeloma care, particularly in underserved communities.
- The program has reached over 5,000 attendees through 50+ educational programs and built a digital community of nearly 60,000 people.
- Survey results will inform future programming, partnerships, and engagement efforts in multiple myeloma care.
The big picture
Bristol Myers Squibb's expansion of the Standing in the Gaap program reflects a growing industry trend toward addressing healthcare disparities through data-driven, community-informed strategies. The initiative aligns with broader efforts to improve access to cancer care, particularly for underserved populations. The program's evolution underscores the strategic importance of patient advocacy partnerships in shaping equitable care solutions.
What we're watching
- Survey Impact
- How the survey findings will shape Bristol Myers Squibb's future equity initiatives in multiple myeloma care.
- Program Scalability
- Whether the expanded Standing in the Gaap program can effectively address broader patient populations.
- Regulatory Alignment
- The pace at which regulatory bodies may respond to or support the program's equity-focused approach.
Related topics